Nirag Jhala
YOU?
Author Swipe
View article: Assessing The Bethesda System for Reporting Thyroid Cytopathology (TBS) Data as a Quality Indicator from a Tertiary Care Institution
Assessing The Bethesda System for Reporting Thyroid Cytopathology (TBS) Data as a Quality Indicator from a Tertiary Care Institution Open
View article: The Critical Need to Expand Proficiency Testing to Cover Telepathology
The Critical Need to Expand Proficiency Testing to Cover Telepathology Open
To the Editor.—In current pathology practice, laboratory proficiency testing (PT) is the standard of care for most clinical laboratory testing.1,2 PT is a critical external quality assessment involving unknown specimens that are sent to cl…
View article: The Critical Value of Telepathology in the COVID-19 Era
The Critical Value of Telepathology in the COVID-19 Era Open
Though barriers to implementation exist, there are potential benefits, such as the wide spectrum of uses like frozen section, telecytology, primary diagnosis, and second opinions. Telepathology represents an innovation that may transform t…
View article: Standardisation of EUS-guided FNB technique for molecular profiling in pancreatic cancer: results of a randomised trial
Standardisation of EUS-guided FNB technique for molecular profiling in pancreatic cancer: results of a randomised trial Open
View article: Data from A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus
Data from A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus Open
Background: Better methods are needed to predict risk of progression for Barrett's esophagus. We aimed to determine whether a tissue systems pathology approach could predict progression in patients with nondysplastic Barrett's esoph…
View article: Supplementary Tables S1-S5, Figures S1-S2, Methods from A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus
Supplementary Tables S1-S5, Figures S1-S2, Methods from A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus Open
Table S1. Summary of Progression Endpoints in Incident Progressor Patients. Table S2. Correlation Among Quantitative Image Analysis Features Derived from the Same Candidate Biomarkers. Table S3. Comparison of Predictive Performance of Risk…
View article: Data from A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus
Data from A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus Open
Background: There is a need for improved tools to detect high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus. In previous work, we demonstrated that a 3-tier classifier predicted risk …
View article: Supplementary Data from A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus
Supplementary Data from A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus Open
Table S1. 15 Image Analysis Features Utilized by the Risk Classifier Table S2. Performance of Risk Classes Predicted by Test vs. Pathologic Diagnosis in Stratifying BE Patients with Prevalent HGD/EAC from Non-Progressor BE Patients. Figure…
View article: Data from A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus
Data from A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus Open
Background: Better methods are needed to predict risk of progression for Barrett's esophagus. We aimed to determine whether a tissue systems pathology approach could predict progression in patients with nondysplastic Barrett's esoph…
View article: Data from A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus
Data from A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus Open
Background: There is a need for improved tools to detect high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus. In previous work, we demonstrated that a 3-tier classifier predicted risk …
View article: Supplementary Data from A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus
Supplementary Data from A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus Open
Table S1. 15 Image Analysis Features Utilized by the Risk Classifier Table S2. Performance of Risk Classes Predicted by Test vs. Pathologic Diagnosis in Stratifying BE Patients with Prevalent HGD/EAC from Non-Progressor BE Patients. Figure…
View article: Supplementary Tables S1-S5, Figures S1-S2, Methods from A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus
Supplementary Tables S1-S5, Figures S1-S2, Methods from A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus Open
Table S1. Summary of Progression Endpoints in Incident Progressor Patients. Table S2. Correlation Among Quantitative Image Analysis Features Derived from the Same Candidate Biomarkers. Table S3. Comparison of Predictive Performance of Risk…
View article: Supplementary Figure 4 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 4 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 4 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Supplementary Figure 5 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 5 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 5 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Supplementary Figure 6 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 6 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 6 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Supplementary Figure 3 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 3 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 3 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Supplementary Figure 6 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 6 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 6 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Data from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Data from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal human malignancies, with an overall 5-year survival rate of <5%. Genetic analysis of PDAC patient samples has shown that specific disease-associated mutations are correlated …
View article: Supplementary Figure 4 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 4 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 4 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Supplementary Figure 2 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 2 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 2 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Data from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Data from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal human malignancies, with an overall 5-year survival rate of <5%. Genetic analysis of PDAC patient samples has shown that specific disease-associated mutations are correlated …
View article: Supplementary Figure 5 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 5 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 5 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Supplementary Figure 3 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 3 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 3 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Supplementary Figure 2 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 2 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 2 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Supplementary Figure 1 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 1 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 1 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Supplementary Figure 1 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia
Supplementary Figure 1 from Inactivation of Smad4 Accelerates Kras<sup>G12D</sup>-Mediated Pancreatic Neoplasia Open
Supplementary Figure 1 from Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
View article: Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages
Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages Open
Introduction Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% of the population and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD ranges from simple steatosis (non-alcoholic fatty liver) to non…
View article: Ensuring remote diagnostics for pathologists: an open letter to the US Congress
Ensuring remote diagnostics for pathologists: an open letter to the US Congress Open
View article: Serous fluid: Reactive conditions
Serous fluid: Reactive conditions Open
This chapter highlights the steps that would help to analyze any fluid. It highlights importance of knowing gross analysis of fluid along with biochemical information. These parameters along with clinical information are very important in …
View article: Serous cavity metastasis: Evaluation of unknown primary
Serous cavity metastasis: Evaluation of unknown primary Open
Malignant effusions can occur in patients with neoplasia. Once a metastatic diagnosis is confirmed, the primary site of origin of malignancy needs to be ascertained. This task can be challenging without a prior history of malignancy. In so…